AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
By Emma Court
Published: Aug 5, 2017 10:25 a.m. ET
Price is a fraught topic in the drug world, but especially so when it comes to hepatitis C, which affects an estimated 3.2 million people and can cause long-term harm or death.
Gilead’s Sovaldi is the disease’s first and best-known treatment. When the therapy came out with an $84,000 price tag, it sent shock waves across the industry and made Sovaldi the poster child for expensive drugs. Critics said the price was too high, but Gilead argued that it was justified by the drug’s value.
Continue reading....
No comments:
Post a Comment